| 1-Glutamine Uptake Inhibitor | 2 | 2 | |
| 1-Leucine Uptake Inhibitor | 1 | 1 | |
| 12-lipoxygenase (12-LOX) | 2 | 2 | |
| 12-lipoxygenase (12-LOX) Inhibitor | 1 | 1 | |
| 15-Lipoxygenase (15-LOX) Inhibitor | 1 | 1 | |
| 17beta-hydroxysteroid dehydrogenase inhibitor | 1 | 1 | |
| 5-alpha reductase inhibitor | 34 | 14 |  |
| 5-HTergic | 1 | 1 | |
| 5-Hydroxyeicosatetraenoic acid (5-HETE) Inhibitor | 1 | 1 | |
| 5-Lipoxygenase Inhibitor | 8 | 7 | |
| 5-Lipoxygenase Inhibitor | 6 | 5 | |
| Abortifacient Agents | 2 | 1 | |
| Acetylcholinesterase Down-Regulation | 2 | 1 | |
| Acetylcholinesterase Inhibitor | 37 | 19 | |
| Acid Blockers | 40 | 16 | |
| Adenosine deaminase inhibitor | 16 | 5 | |
| Adenosine Monophosphate (AMP)-activated Protein Kinase (AMPK | 7 | 2 | |
| Adenosine Monophosphate (AMP)-Activated Protein Kinase (AMPK) Down-Regulation | 2 | 1 | |
| Adiponectin Down-Regulation | 2 | 1 | |
| Adiponectin upregulation | 51 | 11 | |
| Adjuvants: Immunologic | 2 | 1 | |
| Adrenergic Agents | 2 | 1 | |
| Adrenergic Agonists | 2 | 2 | |
| Adrenergic alpha-Agonists | 4 | 3 | |
| Adrenergic alpha-Antagonists | 11 | 2 | |
| Adrenergic beta-Agonists | 3 | 2 | |
| Air Pollutants: Radioactive | 1 | 1 | |
| Akt-dependent HO-1 expression up-regulation | 2 | 1 | |
| AKT-mammalian target of rapamycin (mTOR) pathway inhibitor | 2 | 2 | |
| Akt-SREBP-1 activater | 1 | 1 | |
| Aldose reductase inhibitor | 15 | 4 | |
| Alkylating Agents | 10 | 1 | |
| Alpha-amylase inhibitor | 34 | 20 | |
| Alpha-glucosidase inhibitor | 162 | 111 | |
| Alpha-hemolysin inhibitor | 1 | 1 | |
| Aminopeptidase N (APN/CD13) inhibitor | 1 | 1 | |
| AMP-activated protein kinase modulation | 2 | 2 | |
| Anabolic Agents | 44 | 11 | |
| Analgesics | 2569 | 470 | |
| Analgesics: Non-Narcotic | 25 | 9 | |
| Analgesics: Opioid | 7 | 4 | |
| Androgen Antagonists | 25 | 5 | |
| Androgens | 10 | 1 | |
| Anesthetics | 2 | 1 | |
| Angiogenesis Inducing Agents | 2 | 1 | |
| Angiogenesis Inhibitors | 114 | 62 | |
| Angiogenesis Modulating Agents | 2 | 1 | |
| Angiotensin II Type 1 Receptor Blockers | 4 | 2 | |
| Angiotensin-Converting Enzyme Inhibitors | 24 | 16 | |
| Antacids | 5 | 1 | |
| Anti Inflammatory | 68 | 12 | |
| Anti-Adipogenic | 110 | 52 | |
| Anti-Allergic Agents | 167 | 61 | |
| Anti-Androgen | 60 | 18 | |
| Anti-Angiogenic | 282 | 192 | |
| Anti-Anxiety Agents | 356 | 59 | |
| Anti-Apoptotic | 1620 | 932 | |
| Anti-Arrhythmia Agents | 2 | 1 | |
| Anti-Asthmatic Agents | 24 | 3 | |
| Anti-atherogenic | 156 | 39 | |
| Anti-bacterial | 1 | 1 | |
| Anti-Bacterial Agents | 2088 | 821 | |
| Anti-Cachexic Agents | 2 | 1 | |
| Anti-cancer | 1 | 1 | |
| Anti-collagenase | 13 | 2 | |
| Anti-edemic | 12 | 2 | |
| Anti-elastase | 2 | 2 | |
| Anti-Estrogenic | 3 | 1 | |
| Anti-Fibrotic | 46 | 29 | |
| Anti-Glycation Agents | 46 | 19 | |
| Anti-HIV Agents | 111 | 63 | |
| Anti-Infective Agents | 43 | 18 | |
| Anti-Infective Agents: Urinary | 3 | 2 | |
| Anti-Inflammatory Agents | 12461 | 4729 | |
| Anti-Inflammatory Agents: Non-Steroidal | 4 | 2 | |
| Anti-leukemia Effects | 2 | 1 | |
| Anti-metastatic | 1284 | 927 | |
| Anti-Platelet | 125 | 38 | |
| Anti-Proliferative | 59 | 52 | |
| Anti-Psychotic | 1 | 1 | |
| Anti-pyretic | 28 | 9 | |
| Anti-Retroviral Agents | 16 | 1 | |
| Anti-thrombotic | 56 | 24 | |
| Anti-Tumor | 146 | 73 | |
| Anti-Ulcer Agents | 390 | 140 | |
| Antibacterial Effects | 1 | 1 | |
| Antibiotics: Antifungal | 1 | 1 | |
| Anticarcinogenic Agents | 1577 | 756 | |
| Anticholesteremic Agents | 2126 | 382 | |
| Anticholinergic | 4 | 2 | |
| Anticoagulants | 3 | 2 | |
| Anticonvulsants | 534 | 146 | |
| Antidepressive Agents | 2853 | 522 | |
| Antidepressive Agents: Second-Generation | 1 | 1 | |
| Antidiarrheals | 110 | 20 | |
| Antidiuretic Agents | 2 | 1 | |
| Antiemetics | 40 | 4 | |
| Antifibrinolytic Agents | 1 | 1 | |
| Antifungal Agents | 403 | 237 | |
| Antigiardial agents | 4 | 2 | |
| Antihypertensive Agents | 2852 | 424 | |
| Antilipemic Agents | 10 | 1 | |
| Antilipolytic | 1 | 1 | |
| Antimalarials | 41 | 24 | |
| Antimicrobial | 776 | 352 | |
| Antimitotic Agents | 2 | 2 | |
| Antimutagenic Agents | 164 | 99 | |
| Antimycobacterial | 35 | 19 | |
| Antineoplastic Agents | 1594 | 982 | |
| Antinitrosation | 2 | 1 | |
| Antinoceceptive | 492 | 153 | |
| Antioxidant | 9 | 4 | |
| Antioxidant Effects | 15 | 4 | |
| Antioxidants | 14410 | 5758 | |
| Antiparasitic Agents | 150 | 84 | |
| Antiparkinson Agents | 2 | 1 | |
| Antiproliferative | 4773 | 3450 | |
| Antiprotozoal Agents | 47 | 19 | |
| Antipruritics | 2 | 1 | |
| Antipsychotic Agents | 15 | 2 | |
| Antispasmodic | 132 | 32 | |
| Antithrombotic | 4 | 2 | |
| Antitubercular Agents | 12 | 3 | |
| Antitussive Agents | 12 | 2 | |
| Antiurolithiatic | 20 | 2 | |
| Antiviral Agents | 1307 | 596 | |
| Anxiolytic | 379 | 57 | |
| Apaf-1/caspase-dependent apoptotic pathway activator | 1 | 1 | |
| Aphrodisiac | 63 | 20 | |
| Apoptotic | 5217 | 3846 | |
| Appetite Depressants | 8 | 4 | |
| Appetite Stimulants | 10 | 1 | |
| Appetite Suppresant | 26 | 6 | |
| Arginase 1 (Arg1) up-regulation | 1 | 1 | |
| Arginine Vasopressin (AVP) up-regulation. | 2 | 1 | |
| Aromatase Inhibitors | 37 | 27 | |
| Arylesterase down-regulation | 2 | 1 | |
| Astringents | 1 | 1 | |
| Atrial Natriuretic Factor Modulation | 3 | 2 | |
| Autophagy Inhibitors | 26 | 13 | |
| Autophagy Up-regulation | 296 | 197 | |
| Bax/Bcl2 Ratio: Decrease | 15 | 9 | |
| Bax/Bcl2 ratio: Increase | 25 | 19 | |
| Bcl-2 protein down-regulation | 419 | 295 | |
| Bcl-xL down-regulation | 1 | 1 | |
| Benzodiazepine receptor agonist | 8 | 6 | |
| Beta-Defensin-2 Up-Regulation | 1 | 1 | |
| Bone Density Conservation Agents | 6 | 3 | |
| Brain-Associated Sulfotransferase Down-Regulation | 1 | 1 | |
| Brain-derived neurotrophic factor modulator | 18 | 5 | |
| BRCA-1 Downregulation | 2 | 2 | |
| Breast cancer resistance protein (BCRP) down-regulation | 1 | 1 | |
| Bronchoconstrictor Agents | 2 | 1 | |
| Bronchodilator Agents | 56 | 12 | |
| C-Jun N-Terminal Kinases (JNK) Modulator | 2 | 2 | |
| Calcium Channel Blockers | 87 | 23 | |
| Calcium Desensitizer | 2 | 1 | |
| Calcium/calmodulin dependent protein kinase II inhibitor | 1 | 1 | |
| cAMP up-regulation | 10 | 1 | |
| Cancerous inhibitor of protein phosphatase 2A inhibitor | 1 | 1 | |
| Cannabinoid Receptor Antagonist/Inverse Agonist | 1 | 1 | |
| Carbonyl Reductase 1Inhibitor | 1 | 1 | |
| Carcinogens | 31 | 2 | |
| Cardioprotective | 3412 | 1032 | |
| Cardiotonic Agents | 46 | 7 | |
| Cardiovascular Agents | 160 | 24 | |
| Carminative | 12 | 2 | |
| Caspase-14 Upregulation | 1 | 1 | |
| Caspase-2 Activation | 1 | 1 | |
| Caspase-3 Activation | 137 | 90 | |
| Caspase-3 Inhibition | 4 | 2 | |
| Caspase-7 Activation | 2 | 2 | |
| Caspase-8 activation | 27 | 6 | |
| Caspase-9 Activation | 30 | 19 | |
| Catalase Up-Regulation | 118 | 42 | |
| Cell cycle arrest | 1289 | 1006 | |
| Cell Differentiation Inducer | 6 | 5 | |
| Central Nervous System Agents | 2 | 1 | |
| Central Nervous System Depressants | 10 | 1 | |
| Chelating Agents | 12 | 1 | |
| Chemokine (C-C motif) Ligand 2 (CCL2) Down-Regulation | 3 | 2 | |
| Chemopreventive | 4220 | 1326 | |
| Chemoprotective Agents | 356 | 146 | |
| Chemosensitizer | 772 | 577 | |
| Chemosterilants | 1 | 1 | |
| Chemotherapeutic | 397 | 152 | |
| Chemotherapeuticm | 1 | 1 | |
| Cholagogues and Choleretics | 54 | 12 | |
| Cholecystokinin (CCK) Up-regulation | 34 | 5 | |
| Cholecystokinin Releaser | 20 | 2 | |
| Cholinergic Agents | 3 | 2 | |
| Cholinergic Antagonists | 3 | 2 | |
| Cholinesterase Inhibitors | 10 | 8 | |
| Chondroprotective | 1 | 1 | |
| Chymotrypsin Inhibitor | 21 | 2 | |
| Cicatrizing | 2 | 1 | |
| Coccidiostats | 2 | 1 | |
| Contraceptive Agents | 1 | 1 | |
| Contraceptive Agents: Male | 4 | 2 | |
| Cryoprotective Agents | 1 | 1 | |
| Cyclin D1 Down-Regulation | 42 | 28 | |
| Cyclin-Dependent Kinase 4 Down-Regulation | 1 | 1 | |
| Cyclin-Dependent Kinase Inhibitor | 3 | 3 | |
| Cyclin-Dependent Kinase Inhibitor: P16 | 2 | 2 | |
| Cyclin-dependent kinase inhibitor: P16INK4 | 1 | 1 | |
| Cyclooxygenase 1 Inhibitor | 34 | 27 | |
| Cyclooxygenase 2 Inhibitors | 1114 | 645 | |
| Cyclooxygenase Inhibitors | 71 | 39 | |
| CYP1A1 Transcription Inhibitor | 2 | 1 | |
| CYP3A enzyme induction | 10 | 1 | |
| Cytoprotective | 190 | 94 | |
| Cytotoxic | 76 | 60 | |
| Cytotoxins | 1 | 1 | |
| Death receptor up-regulation | 2 | 1 | |
| Dermatologic Agents | 240 | 28 | |
| Detoxifier | 512 | 171 | |
| Detoxifier: Radionuclide Removal | 23 | 4 | |
| Diacylglyceride acyltransferase 1 (DGAT1) Inhibition | 10 | 1 | |
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 1 | |
| Disinfectants | 1 | 1 | |
| Diuretics | 53 | 11 | |
| DNA Repair Up-regulation | 67 | 16 | |
| Dopamine Agents | 12 | 2 | |
| Dopamine Agonists | 1 | 1 | |
| Dopamine Antagonists | 1 | 1 | |
| Dopamine Receptor D3 Antagonist | 1 | 1 | |
| Dopaminergic | 32 | 10 | |
| Drug sparing | 10 | 1 | |
| Drug synergy | 40 | 11 | |
| E-cadherin down-regulation | 1 | 1 | |
| Emmenagogue | 1 | 1 | |
| Endocannabinoid down-regulation | 12 | 2 | |
| Endocannabinoid Modulator | 1 | 1 | |
| Endothelin-1 Inhibitor | 2 | 1 | |
| Enkephalinase inhibitor | 1 | 1 | |
| Enoyl-acyl Carrier Protein (ACP) Reductase Inhibitors | 1 | 1 | |
| Environmental Pollutants | 2 | 1 | |
| Enzyme Activators | 4 | 2 | |
| Enzyme Inhibitors | 602 | 312 | |
| Enzyme Inhibitors: Maltase Inhibition | 2 | 1 | |
| Enzyme Inhibitors: Pancreatic Amylase | 1 | 1 | |
| Enzyme Inhibitors: Pancreatic Lipase | 12 | 2 | |
| EpCAM surface marker down-regulation | 1 | 1 | |
| Epidermal growth factor receptor (EGFR) inhibitor | 65 | 41 | |
| ER alpha receptor up-regulation | 2 | 1 | |
| ER beta receptor up-regulation | 2 | 1 | |
| Ergogenic | 43 | 6 | |
| Erk/MAP Inactivation | 1 | 1 | |
| Eryptotic | 1 | 1 | |
| Erythropoietic | 4 | 3 | |
| Estradiol 3-glucuronide enhancer | 3 | 3 | |
| Estradiol Antagonists | 2 | 1 | |
| Estrogen Antagonists | 3 | 1 | |
| Estrogen Receptor Agonist | 2 | 2 | |
| Estrogen Receptor Modulators | 51 | 31 | |
| Excitatory Amino Acid Agonists | 7 | 4 | |
| Expectorants | 1 | 1 | |
| Extracellular Signal-Regulated Kinases Modulator | 5 | 4 | |
| Fatty Acid Oxidation | 10 | 1 | |
| Fatty Acid Synthesis Inhibitors | 1 | 1 | |
| Fertility Agents | 2 | 1 | |
| Fertility Agents: Female | 10 | 1 | |
| Fertility Agents: Male | 60 | 14 | |
| Fibrinolytic Agents | 28 | 6 | |
| Fibroblast growth factor 21 upregulation | 2 | 1 | |
| Follicle-stimulating hormone receptor (FSHR) up-regulation | 2 | 1 | |
| Food Preservatives | 1 | 1 | |
| Forkhead Transcription Factor Family O (FOXO) Modulator | 3 | 2 | |
| GABA Modulators | 11 | 7 | |
| Galactogogue | 73 | 8 | |
| Gastric Inhibitory Polypeptide Up-Regulation | 10 | 1 | |
| Gastrointestinal Agents | 268 | 41 | |
| Gastroprotective | 534 | 228 | |
| Gene Protective | 2 | 1 | |
| Genoprotective | 413 | 148 | |
| Ghrelin Down-Regulation | 36 | 6 | |
| Ghrelin Up-regulation | 4 | 2 | |
| Glucagon Like Peptide 1 (GLP-1) Down-Regulation | 35 | 6 | |
| Glucagon Like peptide 1 (GLP-1) Up-regulation | 125 | 33 | |
| Gluconeogenesis Inhibitor | 19 | 14 | |
| Glucose transporter-1 (GLUT1) expression down-regulation | 2 | 2 | |
| Glucose transporter-2 (GLUT2) expression down-regulation | 3 | 2 | |
| Glucose transporter-2 (GLUT2) expression up-regulation | 10 | 1 | |
| Glucose transporter-5 (GLUT5) expression down-regulation | 1 | 1 | |
| Glucose Uptake Optimization | 16 | 1 | |
| Glutathione peroxidase 1 (GPx1) inhibitors | 10 | 1 | |
| Glutathione Peroxidase 1 (GPx1) Up-Regulation | 3 | 2 | |
| Glutathione S-transferase Inhibitor | 4 | 3 | |
| Glutathione Upregulation | 152 | 53 | |
| Glycine Agents | 2 | 1 | |
| Glycogen synthase kinase-3beta (GSK-3beta) Inhibitor | 14 | 4 | |
| Glyoxalase 1 inhibitor | 1 | 1 | |
| Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhibitor | 1 | 1 | |
| Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Upregulation | 4 | 2 | |
| GSH-Px Up-Regulation | 2 | 1 | |
| Heat Shock Protein Down-Regulation | 1 | 1 | |
| Heat Shock Protein Inducer | 83 | 30 | |
| Hematologic Agents | 1 | 1 | |
| Hematopoietic | 20 | 9 | |
| Heme oxygenase-1 inducer | 8 | 5 | |
| Heme oxygenase-1 up-regulation | 73 | 40 | |
| Hemolytic Agents | 1 | 1 | |
| Hepatocyte growth factor (HGF) inhibitor | 15 | 4 | |
| Hepatoprotective | 3182 | 1418 | |
| HER-2 oncoprotein down-regulation | 2 | 1 | |
| Herbicides | 1 | 1 | |
| High-mobility group box-1 (HMGB1) inhibitor | 2 | 1 | |
| Histamine Agents | 2 | 1 | |
| Histamine Agonists | 2 | 1 | |
| Histamine Antagonists | 45 | 17 | |
| Histamine Antagonists | 45 | 17 | |
| Histamine down-regulation | 3 | 2 | |
| Histamine H2 Antagonists | 2 | 2 | |
| Histamine up-regulation | 1 | 1 | |
| Histone deacetylase inhibitor | 48 | 37 | |
| HIV Fusion Inhibitors | 5 | 4 | |
| HIV Protease Inhibitors | 29 | 17 | |
| HIV-1 Integrase Inhibitor | 3 | 3 | |
| HMG-CoA reductase inhibitor | 3 | 2 | |
| Hormones | 10 | 1 | |
| Human androgen receptor (AR) antagonist | 2 | 2 | |
| Human Polymorphonuclear Leukocyte Degranulation Inhibitor | 1 | 1 | |
| Hydroperoxidase Inhibitor | 2 | 1 | |
| Hydroxyheptadecatrienoate (HHT) Inhibitor | 1 | 1 | |
| Hypnotics and Sedatives | 20 | 6 | |
| Hypoglycemic Agents | 3297 | 841 | |
| Hypolipidemic | 3189 | 707 | |
| Hypomethylating | 1 | 1 | |
| Hypotensive | 435 | 59 | |
| Hypoxia inducible factor-1 alpha (HIF-1α) inhibitor | 22 | 15 | |
| Hypoxia-inducible factor-1 (HIF-1) inhibitor | 1 | 1 | |
| IGF-1R expression down-regulation | 1 | 1 | |
| Immune Enhancing Properties | 10 | 1 | |
| Immunomodulatory | 2249 | 733 | |
| Immunomodulatory: CD23+ Mature Macrophage Down-Regulation | 10 | 1 | |
| Immunomodulatory: CD8+ Up-regulation | 2 | 1 | |
| Immunomodulatory: Immunoglobulin G up-regulation | 10 | 1 | |
| Immunomodulatory: Immunoglobulin M Up-Regulation | 10 | 1 | |
| Immunomodulatory: Innate Immunity Up-Regulation | 12 | 2 | |
| Immunomodulatory: Regulatory T Cell Up-Regulation | 4 | 2 | |
| Immunomodulatory: T-Cell down-regulation | 12 | 2 | |
| Immunomodulatory: Th17 downregulation | 30 | 17 | |
| Immunostimulatory | 442 | 114 | |
| Immunostimulatory: IgA Production Up-Regulation | 10 | 1 | |
| Immunosuppressive Agents | 37 | 24 | |
| Incretin Modulator | 2 | 1 | |
| Inhibitor of Nuclear Factor Kappa-B Kinase (IKK) | 2 | 2 | |
| Insect Repellents | 1 | 1 | |
| Insecticidal | 8 | 4 | |
| Insecticides | 2 | 1 | |
| Insulin Antagonists | 10 | 1 | |
| Insulin Down-Regulation | 12 | 2 | |
| Insulin Receptor Modulator | 12 | 2 | |
| Insulin Sensitizers | 707 | 139 | |
| Insulin-Like Growth Factor Enhancer/Upregulation | 5 | 3 | |
| Insulin-Like Growth Factor Inhibition/Downregulation | 76 | 17 | |
| Insulin-mimetic | 9 | 6 | |
| Insulin-releasing | 62 | 28 | |
| Insulinotrophic | 11 | 7 | |
| Intercellular adhesion molecule 3 down-regulation | 3 | 2 | |
| Interferon Gamma Reducer | 58 | 24 | |
| Interferon Inducers | 31 | 9 | |
| Interferon-gamma (IFN-gamma) inducer | 24 | 8 | |
| Interleukin 1 receptor antagonist (IL-1Ra) up-regulation | 10 | 1 | |
| Interleukin-1 alpha downregulation | 42 | 17 | |
| Interleukin-1 alpha upregulation | 3 | 2 | |
| Interleukin-1 beta downregulation | 1743 | 868 | |
| Interleukin-1 beta upregulation | 1 | 1 | |
| Interleukin-1 receptor antagonist | 11 | 2 | |
| Interleukin-10 downregulation | 284 | 103 | |
| Interleukin-10 upregulation | 105 | 24 | |
| Interleukin-12 downregulation | 9 | 5 | |
| Interleukin-12 upregulation | 17 | 5 | |
| interleukin-13 down-regulation | 2 | 1 | |
| Interleukin-13 Up-Regulation | 10 | 1 | |
| Interleukin-15 downregulation | 3 | 2 | |
| Interleukin-17 downregulation | 39 | 13 | |
| Interleukin-17 upregulation | 4 | 2 | |
| Interleukin-18 down-regulation | 20 | 7 | |
| Interleukin-18 upregulation | 1 | 1 | |
| Interleukin-2 Downregulation | 4 | 3 | |
| Interleukin-2 upregulation | 43 | 8 | |
| Interleukin-21 downregulation | 2 | 1 | |
| Interleukin-22 Downregulation | 10 | 1 | |
| Interleukin-23 Downregulation | 10 | 1 | |
| Interleukin-3 upregulation | 10 | 1 | |
| Interleukin-4 downregulation | 119 | 34 | |
| Interleukin-4 upregulation | 12 | 2 | |
| Interleukin-5 downregulation | 25 | 4 | |
| Interleukin-5 upregulation | 2 | 1 | |
| Interleukin-6 Downregulation | 3054 | 1144 | |
| Interleukin-6 upregulation | 26 | 7 | |
| Interleukin-8 downregulation | 406 | 147 | |
| Interleukin-8 upregulation | 20 | 2 | |
| Intracellular adhesion molecule down-regulation | 10 | 1 | |
| Intracellular adhesion molecule-1 (ICAM-1) | 4 | 3 | |
| IRAK-MAPK Modulator | 1 | 1 | |
| Iron Chelating Agents | 4 | 3 | |
| Isoprostane Down-Regulation | 10 | 1 | |
| JAM3 gene down-regulation | 2 | 1 | |
| Lactate Dehydrogenase A Inhibitor | 1 | 1 | |
| Laxative | 42 | 6 | |
| Leishmanicidal | 38 | 24 | |
| Leptin Down-Regulation | 13 | 3 | |
| Leukotriene Antagonists | 38 | 9 | |
| Leukotriene B4 downregulation | 13 | 4 | |
| Leukotriene C4 Downregulation | 2 | 2 | |
| Leukotriene D4 antagonist | 1 | 1 | |
| Lipolytic | 45 | 16 | |
| Lipotropic Agents | 2 | 1 | |
| Lipoxygenase Inhibitors | 38 | 17 | |
| Lymphagogue | 2 | 1 | |
| Malonaldehyde (MDA) Down-Regulation | 20 | 6 | |
| Malondialdehyde Down-regulation | 1452 | 466 | |
| Maspin (Protease Inhibitor) Up-Regulation | 1 | 1 | |
| Mast Cell Activation Inhibitor | 1 | 1 | |
| Matrix metalloproteinase-1 (MMP-1) inhibitor | 32 | 16 | |
| Matrix Metalloproteinase-12 (MMP-12) Inhibitor | 2 | 1 | |
| Matrix Metalloproteinase-13 (MMP-13) Inhibitor | 23 | 11 | |
| Matrix metalloproteinase-14 (MMP-14) inhibitor | 1 | 1 | |
| Matrix metalloproteinase-16 (MMP-16) inhibitor | 1 | 1 | |
| Matrix metalloproteinase-17 (MMP-17) inhibitor | 1 | 1 | |
| Matrix metalloproteinase-2 (MMP-2) inhibitor | 551 | 315 | |
| Matrix metalloproteinase-3 (MMP-3) inhibitor | 61 | 18 | |
| Matrix Metalloproteinase-7 (MMP-7) Inhibitor | 4 | 1 | |
| Matrix metalloproteinase-8 (MMP-8) inhibitor | 3 | 2 | |
| Matrix Metalloproteinase-8 Inhibitor | 1 | 1 | |
| Matrix metalloproteinase-9 (MMP-9) inhibitor | 543 | 337 | |
| Matrix Metalloproteinases Inhibitors | 3 | 2 | |
| Metal Chelation: Copper | 1 | 1 | |
| Metallothionein Up-regulation | 12 | 2 | |
| MicroRNA modulator | 264 | 145 | |
| Mitochondrial Superoxide Dismutase Upregulation | 4 | 3 | |
| Mitogen-activated protein kinase inhibitors | 11 | 2 | |
| Mitogen-activated protein kinase kinase 4 (MEK4) | 11 | 2 | |
| Molecular Probes | 1 | 1 | |
| Monoamine Oxidase Inhibitors | 4 | 2 | |
| Monoaminergic | 6 | 3 | |
| Monocyte chemotattractant protein-1 (MCP-1) Inhibitor | 1 | 1 | |
| mTOR/S6K pathway Activator | 1 | 1 | |
| Mucolytic | 12 | 2 | |
| Multidrug Resistance Gene Modulators | 20 | 15 | |
| Muscarinic Agonists | 2 | 1 | |
| Muscarinic Antagonists | 2 | 2 | |
| Muscle Relaxants: Central | 1 | 1 | |
| Myorelaxant | 2 | 1 | |
| Myosin heavy chain alpha (MHCalpha) reducer | 2 | 1 | |
| NADPH Oxidase Inhibitors | 1 | 1 | |
| Natriuretic Agents | 23 | 4 | |
| Neocardiogenic | 8 | 7 | |
| Neocardiogenic | 8 | 7 | |
| Neovasculogenesis | 1 | 1 | |
| Neuritogenic | 133 | 59 | |
| Neurogenesis | 59 | 30 | |
| Neuroimmunomodulation | 1 | 1 | |
| Neurominidase Inhibitor | 17 | 16 | |
| Neuromodulatory | 2 | 1 | |
| Neuroplasticity enhancement | 44 | 12 | |
| Neuroprotective Agents | 6374 | 2801 | |
| Neurorestorative | 71 | 21 | |
| Neurotransmitter Uptake Inhibitors | 10 | 1 | |
| Neutrophil Activation: Down-Regulation | 2 | 1 | |
| Neutrophil Rolling Inhibitor | 2 | 1 | |
| NF-E2-Related Factor-2 (Nrf2) Modulator | 48 | 26 | |
| NF-kappa-B-inducing kinase (NIK) modulator | 3 | 2 | |
| NF-kappaB Inhibitor | 2446 | 1436 | |
| Nitric Oxide Enhancer | 190 | 47 | |
| Nitric Oxide Inhibitor | 390 | 196 | |
| Nonpeptidyl Inhibitors | 1 | 1 | |
| Nootropic Agents | 2 | 1 | |
| Noradrenergic | 2 | 1 | |
| NOX2 inhibitor | 10 | 1 | |
| Nrf2 activation | 177 | 86 | |
| Oncogene Suppressor | 15 | 11 | |
| Opioid Endogenous Up-regulation | 2 | 1 | |
| Osteogenic | 52 | 12 | |
| Osteoprotective | 20 | 6 | |
| Ovogenic | 2 | 1 | |
| Oxidants | 1 | 1 | |
| Oxytocics | 1 | 1 | |
| Oxytocin inducer | 10 | 1 | |
| P-glycoprotein Inhibitors | 2 | 2 | |
| P16 Activation | 1 | 1 | |
| P21 Activation | 72 | 47 | |
| p300/NF-κB down-regulation | 1 | 1 | |
| P38 Mitogen-Activated Protein Kinase Modulator | 6 | 5 | |
| Palmitoylation Inhibitors | 1 | 1 | |
| Pancreato Protective Agents | 40 | 23 | |
| Paraoxonase down-regulation | 2 | 1 | |
| Paraptosis | 1 | 1 | |
| Peptide YY (PYY) Down-regulation | 10 | 1 | |
| Peptide YY (PYY) Up-Regulation | 16 | 4 | |
| PER2 Protein Expression Up-regulation | 10 | 1 | |
| Peroxisome Proliferators | 2 | 1 | |
| Phase I Detoxification Enzyme Inducer | 4 | 2 | |
| Phase I Detoxification Enzyme Inhibitor | 2 | 1 | |
| Phase II Detoxification Enzyme Inducer | 78 | 40 | |
| Phosphodiesterase Inhibitors | 1 | 1 | |
| Phospholipase D Inhibitors | 1 | 1 | |
| Phosphorylase Kinase Inhibitors | 10 | 1 | |
| Phosphorylated Rb Down-Regulation | 1 | 1 | |
| Photoprotective | 74 | 27 | |
| Photosensitizing Agents | 1 | 1 | |
| PI3K-AKT inhibitor | 1 | 1 | |
| PI3K/Akt/signaling suppression | 1 | 1 | |
| PKM2 downregulation | 1 | 1 | |
| Platelet aggregation inhibitor: collagen-induced aggregation | 1 | 1 | |
| Platelet Aggregation Inhibitors | 186 | 40 | |
| Postaglandin PGE2 downregulation | 23 | 11 | |
| PPAR-Gamma Up-Regulation | 1 | 1 | |
| PRL-3 Down-Regulation | 1 | 1 | |
| Progestagenic | 2 | 1 | |
| Progesterone receptor (PR) up-regulation | 2 | 1 | |
| Prophylactic Agents | 129 | 31 | |
| Prostaglandin Antagonists | 27 | 13 | |
| Prostaglandin E Synthase-1 (PGES-1) Down-Regulation | 2 | 1 | |
| Prostaglandin H Synthase-1 (PGHS-1) Inhibits | 1 | 1 | |
| Prostaglandin H Synthase-2 (PGHS-2) Up-Regulation | 1 | 1 | |
| Prostaglandin PGE2 downregulation | 187 | 83 | |
| Prostaglandin PGF2 downregulation | 2 | 2 | |
| Protease Inhibitors | 15 | 6 | |
| Proteasome Inhibitors | 51 | 33 | |
| Protein Kinase C Inhibitor | 1 | 1 | |
| Protein Kinase Inhibitors | 17 | 13 | |
| Protein tyrosine phosphatase 1B (PTP1B) modulator | 4 | 2 | |
| Proton Pump Inhibitor | 36 | 13 | |
| Psychedelic | 1 | 1 | |
| Quinone Reductase-Inducer | 3 | 2 | |
| Quorum Sensing Inhibition | 1 | 1 | |
| Radiation-Protective Agents | 4 | 2 | |
| Radiation-Sensitizing Agents | 1 | 1 | |
| Radiopharmaceuticals | 1 | 1 | |
| Radioprotective | 1247 | 406 | |
| Radiosensitizer | 244 | 142 | |
| RANK Downregulation | 1 | 1 | |
| RANTES (CCL5) Inhibitor | 2 | 2 | |
| Reactive Oxygen Species (ROS) attenuation | 1 | 1 | |
| Receptor activator of NF-κB (RANK) gene expression | 2 | 2 | |
| Receptor-Related Orphan Receptor (ROR)-Alpha1 Inhibitor | 2 | 1 | |
| Redox Balancer | 2 | 1 | |
| Redox Modulator | 5 | 3 | |
| Regenerative | 52 | 28 | |
| Remyelination | 2 | 1 | |
| Renoprotective | 1308 | 593 | |
| Respiratory System Agents | 10 | 1 | |
| Reverse Transcriptase Inhibitors | 42 | 24 | |
| Ribonucleotide Reductase Inhibitor | 1 | 1 | |
| S-phase kinase associated protein 2 inhibition | 1 | 1 | |
| Sarcoplasmic Calcium ATPase Up-regulation | 2 | 1 | |
| Schistosomicides | 2 | 1 | |
| Scolicidal | 1 | 1 | |
| Secretagogue | 178 | 38 | |
| Secretagogues: Prolactin Up-Regulation | 1 | 1 | |
| Selective estrogen enzyme modulator (SEEM) | 11 | 8 | |
| Selective Estrogen Receptor Modulators | 10 | 6 | |
| Serine Proteinase Inhibitors | 1 | 1 | |
| Serotonergic | 32 | 8 | |
| Serotonin Agonists | 2 | 1 | |
| Serum ceruloplasmin oxidase reducer | 2 | 1 | |
| SGLT1 inducer | 4 | 2 | |
| SGLT1 inducer | 4 | 2 | |
| Sigma-1 Receptor Agonist | 2 | 2 | |
| SIRT1 Activator | 39 | 23 | |
| Spasmogenic | 2 | 1 | |
| Spermatogenic | 12 | 2 | |
| Spermicidal Activity | 5 | 1 | |
| STAT3 Activation | 2 | 1 | |
| STAT3 Inhibitor | 53 | 31 | |
| STAT3-NFκB Signaling: downregulation | 1 | 1 | |
| Stearoyl coenzyme A desaturase-1 modulator | 2 | 1 | |
| Steroidogenesis | 3 | 2 | |
| Stomachic | 2 | 1 | |
| Sulfonation | 1 | 1 | |
| Superoxide Dismutase Up-regulation | 1039 | 415 | |
| Superoxide Scavenger | 1 | 1 | |
| Survival protein down-regulation | 3 | 2 | |
| Survivin Down-Regulation | 15 | 13 | |
| Telomerase Inhibitor | 55 | 35 | |
| Telomerase Upregulation | 102 | 28 | |
| Telomere Protective | 83 | 10 | |
| Teratogens | 14 | 3 | |
| Thermogenic | 57 | 9 | |
| Thrombolytic | 4 | 2 | |
| Thromboxane (TXB) Inhibitors | 5 | 4 | |
| Thromboxane B2 Inhibitor | 2 | 2 | |
| Tocolytic Agents | 11 | 2 | |
| Topoisomerase I inhibitor | 1 | 1 | |
| Topoisomerase II Inhibitor | 3 | 3 | |
| TRAIL sensitizer | 3 | 2 | |
| Transforming growth factor beta (TGF-β) inhibitor | 32 | 9 | |
| Transforming growth factor beta (TGF-β) upregulation | 2 | 1 | |
| Transient Receptor Potential Melastatin 2 Inhibition | 1 | 1 | |
| Transient receptor potential vanilloid type-2 activation | 1 | 1 | |
| Trypanocidal Agents | 2 | 2 | |
| Trypsin Inhibitors | 2 | 1 | |
| Tumor Necrosis Factor (TNF) Alpha Enhancer | 38 | 8 | |
| Tumor Necrosis Factor (TNF) Alpha Inhibitor | 4357 | 1763 | |
| Tumor Necrosis Factor (TNF) Alpha Upregulation | 2 | 1 | |
| Tumor Suppressor Protein p53 Upregulation | 480 | 343 | |
| Tumor Suppressor Protein p73 Upregulation | 3 | 2 | |
| Tyrosinase Inhibition | 1 | 1 | |
| Tyrosinase inhibitors | 4 | 4 | |
| Uncoupling Agents | 2 | 1 | |
| Uricosuric Agents | 2 | 1 | |
| Uterotonic | 34 | 11 | |
| Vanilloid Receptor-1 Modulator | 2 | 2 | |
| Vascular Cell Adhesion Molecule-1 Inhibitor | 117 | 30 | |
| Vascular Endothelial Growth Factor A Enhancer | 4 | 2 | |
| Vascular Endothelial Growth Factor A Inhibitor | 132 | 71 | |
| Vascular Endothelial Growth Factor C Inhibitor | 2 | 1 | |
| Vascular Endothelial Growth Factor D Inhibitor | 2 | 1 | |
| Vascular Endothelial Growth Factor Inhibitors | 123 | 61 | |
| Vascular Endothelial Growth Factor Regulator | 31 | 14 | |
| Vascular smooth muscle cell (VSMC) inhibitor | 7 | 5 | |
| Vasodilator Agents | 347 | 74 | |
| Vasopressin Inhibitor | 12 | 2 | |
| Vasoprotective | 21 | 9 | |
| VEGFR3 inhibition | 12 | 3 | |
| Viral Hemagglutinin Inhibitor | 18 | 14 | |
| Vitamin D Receptor (VDR) Modulator | 1 | 1 | |
| Wnt/β-catenin pathway down-regulation | 49 | 27 | |
| Wnt/β-catenin signaling pathway modulation | 36 | 24 | |
| Wound Healing Effects | 10 | 1 | |
| Xanthine oxidase inhibitor | 26 | 13 | |
| Zinc-dependent metalloproteinase inhibitor | 1 | 1 | |
| β(2)-adrenoceptor up-regulation | 2 | 1 | |
| β-secretase Inhibitor | 1 | 1 | |
Therapeutic Substances
Therapeutic Actions
Problem Substances
Problematic Actions
Adverse Pharmacological Actions
Diseases
Trending Topics
